ESC 365 - The senolyitc drug ABT-263 reverses HFpEF-associated inflammation, endothelial inflammation and fibrosis

HFA Premium Access

The senolyitc drug ABT-263 reverses HFpEF-associated inflammation, endothelial inflammation and fibrosis

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 2

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Miss E. Silva (Porto, PT)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Miss Elsa Silva

I3s (Institute for Research and Innovation in Health), Porto (Portugal)

0 follower

9 more presentations in this session

Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial

Speaker: Doctor C. Lam (Singapore, SG)

Long-term outcomes in heart failure with preserved ejection fraction: predictors of cardiovascular and non-cardiovascular mortality

Speaker: Ms A. Shahim (Stockholm, SE)

The impact of multimorbidity on mortality in heart failure with reduced ejection fraction (HFrEF): Which comorbidities matter most?

Speaker: Doctor P. Dewan (Glasgow, GB)

Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)

Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial

Speaker: Doctor R. Mentz (Durham, US)

Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 2

Speakers: Miss E. Silva, Doctor C. Lam, Ms A. Shahim, Doctor P. Dewan, Doctor K. Docherty...

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources